Glaukos Corporation (GKOS)

Market Cap	6.09B
Revenue (ttm)	404.52M
Net Income (ttm)	-123.68M
Shares Out	57.11M
EPS (ttm)	-2.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	441,421
Open	104.00
Previous Close	104.72
Day's Range	103.39 - 106.82
52-Week Range	77.10 - 163.71
Beta	0.82
Analysts	Strong Buy
Price Target	135.15 (+26.84%)
Earnings Date	Jul 30, 2025

About GKOS

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 995
• Stock Exchange: NYSE
• Ticker Symbol: GKOS
• Website: https://www.glaukos.com

Financial Performance

In 2024, Glaukos's revenue was $383.48 million, an increase of 21.85% compared to the previous year's $314.71 million. Losses were -$146.37 million, 8.70% more than in 2023.

Analyst Summary

According to 13 analysts, the average rating for GKOS stock is "Strong Buy." The 12-month stock price target is $135.15, which is an increase of 26.84% from the latest price.

Price Target

$135.15

(26.84% upside)

Analyst Consensus: Strong Buy